STOCK TITAN

Clarivate Plc - CLVT STOCK NEWS

Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.

About Clarivate Plc

Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, delivering enriched data, insights, analytics, and workflow solutions to accelerate innovation across academia, intellectual property (IP), life sciences, and government sectors. With a mission to empower organizations and researchers to bring life-changing ideas to market faster, Clarivate offers a comprehensive suite of trusted brands, including Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These solutions enable customers to streamline research, manage intellectual property, and optimize pharmaceutical development.

Core Business Areas

Clarivate operates across three primary segments:

  • Academia & Government: Supporting academic institutions and government bodies with data-driven insights, library services, and discovery platforms to enhance research and learning outcomes.
  • Intellectual Property: Providing tools for patent analytics, trademark research, and IP lifecycle management, empowering organizations to protect and monetize their innovations.
  • Life Sciences & Healthcare: Delivering real-world data, analytics, and workflow solutions to pharmaceutical and biotech companies, aiding in drug discovery, regulatory compliance, and market access.

Revenue Model and Market Position

Clarivate primarily generates revenue through subscription-based services, ensuring a predictable and recurring income stream. Its portfolio also includes licensing, transactional sales, and consulting services. With operations in over 100 countries and a customer base spanning academia, government, law, healthcare, and life sciences, Clarivate is uniquely positioned as a critical enabler of innovation. The company’s focus on integrating artificial intelligence (AI) and real-world data into its offerings distinguishes it from competitors in the knowledge economy.

Strategic Initiatives

Clarivate is actively pursuing a Value Creation Plan to enhance its financial performance and operational efficiency. Key initiatives include:

  • Subscription Revenue Growth: Transitioning from low-margin transactional products to high-margin subscription-based solutions.
  • Portfolio Rationalization: Streamlining its product offerings to focus on high-growth, high-impact areas.
  • AI-Driven Innovation: Leveraging advanced technologies like AI-powered patent search and real-world data analytics to enhance customer decision-making.
  • Sales Execution: Realigning account management models and investing in customer success teams to improve client engagement and retention.

Challenges and Opportunities

While Clarivate faces challenges such as fluctuating transactional revenues and market competition, its strategic focus on innovation and recurring revenue streams positions it for long-term growth. The company’s ability to integrate AI and real-world data into its solutions offers significant opportunities to address emerging customer needs and expand its market share.

Competitive Landscape

Clarivate competes with other data and analytics providers like Elsevier, Thomson Reuters, and Springer Nature. Its differentiation lies in its comprehensive suite of products, trusted brands, and commitment to innovation. By focusing on customer-centric solutions and leveraging advanced technologies, Clarivate continues to strengthen its competitive position.

Conclusion

Clarivate Plc is more than a data provider; it is a catalyst for innovation, enabling organizations to accelerate the journey from idea to impact. With a robust portfolio of solutions, a strategic focus on subscription revenue, and a commitment to leveraging cutting-edge technologies, Clarivate remains a pivotal player in the global knowledge economy.

Rhea-AI Summary
Clarivate Plc (CLVT) launches VeriSIM Life Translational Index™ on Cortellis Drug Discovery Intelligence, providing pharma and biotech companies with predictive compound safety and efficacy insights. The integrated workflow aims to minimize late-stage failures during clinical trials, leveraging AI to reduce research and development time and increase clinically active compound candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
partnership
-
Rhea-AI Summary
Clarivate Plc (NYSE:CLVT) reveals its 2023 list of Highly Cited Researchers™, recognizing influential researchers globally. The evaluation process draws on data from the Web of Science™ citation index, with 6,849 researchers from over 1,300 institutions in 67 nations and regions. Key findings show a concentration of top talent, with 10 countries representing over 80% of the list. The US leads with 37.5%, followed by Mainland China with 17.9%. The Chinese Academy of Sciences tops the list with 270 recognitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
none
-
Rhea-AI Summary
Clarivate Plc (NYSE: CLVT) announced that CEO Jonathan Gear will present at the RBC Capital Markets 2023 Technology, Internet, Media and Telecommunications Conference on November 14, 2023 at 1:20 pm Eastern Time. The live webcast can be accessed at https://www.veracast.com/webcasts/rbc/tmit2023/67C540.cfm and will be available for replay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
conferences
Rhea-AI Summary
Clarivate Plc reported third-quarter revenues of $647.2 million, a 1.8% increase, and a net loss of $6.6 million. The company reaffirmed its 2023 outlook, showing improved performance driven by organic growth in its segments. Revenues for the nine months ended September 30, 2023, were $1,945.1 million, a 2.0% decrease, and a net loss of $123.6 million. The company's adjusted EBITDA increased by 3.6% to $281.4 million for the third quarter, and by 1.3% to $819.0 million for the nine months ended September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
-
Rhea-AI Summary
China's research economy has seen a dramatic increase in quality and its research is increasingly valued beyond its borders, according to a report from the Institute for Scientific Information (ISI). China's research output has increased five-fold between 2009 and 2021, surpassing the U.S. and E.U. in published research. China's proportion of published research with citation impact above the global average now matches the U.S. and Germany. Additionally, China has over 1,000 Highly Cited Papers per year, indicating global recognition and collaboration with Chinese researchers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Clarivate Plc has announced a partnership with EveryLibrary to support libraries in the US. The partnership aims to advance EveryLibrary's mission to safeguard and support libraries by providing dedicated resources and advocacy. Clarivate is committed to promoting literacy, education, and equal access to information through this partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
Rhea-AI Summary
BioWorld™ published by Clarivate Plc examines the impact of emerging obesity medicines in a new three-part series. Over $1 billion of investment is anticipated in obesity through licensing or M&As in 2023, with the overall market expected to climb upwards of $50 billion in the coming years. Novo Nordisk recently reported sales of Wegovy totaling $1.7 billion for the first half of 2023, up 367% over the prior year. Sales of Ozempic, a lower-dose version of semaglutide, are up 58% year over year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
-
Rhea-AI Summary
Clarivate renews contract with FEDLINK to provide comprehensive solutions to government libraries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
partnership
-
Rhea-AI Summary
Clarivate Plc to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.06%
Tags
conferences earnings
Rhea-AI Summary
Clarivate Plc releases report on the impact of AI on IP law and practice
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
AI

FAQ

What is the current stock price of Clarivate Plc (CLVT)?

The current stock price of Clarivate Plc (CLVT) is $4.21 as of March 3, 2025.

What is the market cap of Clarivate Plc (CLVT)?

The market cap of Clarivate Plc (CLVT) is approximately 3.0B.

What does Clarivate Plc do?

Clarivate provides data, insights, and workflow solutions to accelerate innovation in academia, intellectual property, and life sciences.

How does Clarivate generate revenue?

Clarivate primarily generates revenue through subscription-based services, licensing, and consulting, ensuring a recurring income stream.

What industries does Clarivate serve?

Clarivate serves academia, government, intellectual property, life sciences, and healthcare sectors, offering tailored solutions for each industry.

What are Clarivate’s key brands?

Clarivate’s key brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™.

What is Clarivate’s Value Creation Plan?

The Value Creation Plan focuses on subscription revenue growth, portfolio rationalization, AI-driven innovation, and improved sales execution.

How does Clarivate use AI in its products?

Clarivate integrates AI into solutions like patent search and real-world data analytics to enhance decision-making and innovation workflows.

What challenges does Clarivate face?

Clarivate faces challenges such as fluctuating transactional revenues, market competition, and the need for continuous product innovation.

Who are Clarivate’s competitors?

Clarivate competes with companies like Elsevier, Thomson Reuters, and Springer Nature in the data and analytics space.

What makes Clarivate unique?

Clarivate’s comprehensive product portfolio, trusted brands, and focus on AI-driven innovation set it apart from competitors.

What are Clarivate’s future growth areas?

Clarivate aims to grow through subscription-based solutions, AI-powered innovation, and expanding its presence in high-impact sectors like life sciences.
Clarivate Plc

NYSE:CLVT

CLVT Rankings

CLVT Stock Data

3.00B
369.56M
16.38%
92.68%
6.23%
Information Technology Services
Services-computer Processing & Data Preparation
Link
United Kingdom
ST. HELIER